3 US Growth Companies To Watch With Up To 32% Insider Ownership

As the United States stock market navigates a volatile period marked by fluctuations in major indices and a notable slump in big-tech stocks, investors are increasingly focused on identifying resilient growth opportunities. In this environment, companies with substantial insider ownership can offer unique insights into potential value creation, as insiders' vested interests often align with long-term shareholder success.

Advertisement

Top 10 Growth Companies With High Insider Ownership In The United States

NameInsider OwnershipEarnings GrowthAtour Lifestyle Holdings (NasdaqGS:ATAT)26%25.7%Super Micro Computer (NasdaqGS:SMCI)14.4%24.3%On Holding (NYSE:ONON)19.1%29.4%Duolingo (NasdaqGS:DUOL)14.6%34.7%Clene (NasdaqCM:CLNN)21.6%59.2%EHang Holdings (NasdaqGM:EH)32.8%81.8%BBB Foods (NYSE:TBBB)22.9%41%Credo Technology Group Holding (NasdaqGS:CRDO)13.3%66.3%Credit Acceptance (NasdaqGS:CACC)14.0%49%Spotify Technology (NYSE:SPOT)17.6%29.7%

Click here to see the full list of 201 stocks from our Fast Growing US Companies With High Insider Ownership screener.

Let's dive into some prime choices out of the screener.

Delcath Systems (NasdaqCM:DCTH)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Delcath Systems, Inc. is an interventional oncology company specializing in the treatment of primary and metastatic liver cancers in the United States and Europe, with a market cap of $382.41 million.

Operations: The company's revenue segment focuses on the development and commercialization of Melphalan/HDS and CHEMOSAT, generating $22.64 million.

Insider Ownership: 11.6%

Delcath Systems is positioned for growth with revenue forecasted to increase by 40.5% annually, outpacing the broader U.S. market. The company recently reported a turnaround in its financials with a net income of US$1.86 million for Q3 2024, compared to a significant loss the previous year. Despite past shareholder dilution and limited cash runway, Delcath's FDA-approved Phase 2 trial for HEPZATO™ could enhance its market presence in liver-dominant metastatic colorectal cancer treatment.

NasdaqCM:DCTH Ownership Breakdown as at Dec 2024
NasdaqCM:DCTH Ownership Breakdown as at Dec 2024

EHang Holdings (NasdaqGM:EH)

Simply Wall St Growth Rating: ★★★★★★

Overview: EHang Holdings Limited is an autonomous aerial vehicle technology platform company operating in China, East Asia, West Asia, Europe, and internationally with a market cap of approximately $1.01 billion.

Operations: The company's revenue segment is Aerospace & Defense, generating CN¥348.48 million.

Insider Ownership: 32.8%

EHang Holdings is poised for growth, with revenue expected to rise 36.9% annually, surpassing the U.S. market average. Insider ownership contributes to strategic stability as the company forms alliances to enhance its low-altitude economy initiatives, including a recent partnership with China Communications Information & Technology Group. Despite past shareholder dilution and high share price volatility, EHang's forecasted profitability and innovative advancements in eVTOL technology position it favorably in the evolving aerial mobility sector.

NasdaqGM:EH Earnings and Revenue Growth as at Dec 2024
NasdaqGM:EH Earnings and Revenue Growth as at Dec 2024

Afya (NasdaqGS:AFYA)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Afya Limited is a medical education group operating in Brazil with a market cap of approximately $1.43 billion.

Operations: The company's revenue is derived from its Undergrad segment, which generated R$2.78 billion, and Continuing Education, contributing R$164.55 million.

Insider Ownership: 16.1%

Afya Limited shows strong growth potential, with earnings forecasted to grow 21.63% annually, outpacing the U.S. market. The company trades at a significant discount to its estimated fair value and reported substantial year-over-year revenue and net income increases for Q3 2024, reflecting robust operational performance. Despite no recent insider trading activity, Afya's reaffirmed financial guidance underscores confidence in achieving BRL 3.23 billion to BRL 3.33 billion in annual revenue for 2024.

NasdaqGS:AFYA Ownership Breakdown as at Dec 2024
NasdaqGS:AFYA Ownership Breakdown as at Dec 2024

Where To Now?

Seeking Other Investments?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqCM:DCTH

Delcath Systems

An interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.

Flawless balance sheet with high growth potential.

Advertisement

Weekly Picks

ST
stuart_roberts
UNCY logo
stuart_roberts on Unicycive Therapeutics ·

Looking to be second time lucky with a game-changing new product

Fair Value:US$21.5371.1% undervalued
33 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
HE
PLY logo
HegelBayeBagel on PlaySide Studios ·

PlaySide Studios: Market Is Sleeping on a Potential 10M+ Unit Breakout Year, FY26 Could Be the Rerate of the Decade

Fair Value:AU$0.8463.1% undervalued
9 users have followed this narrative
2 users have commented on this narrative
5 users have liked this narrative
AN
AnimalDoctorKwon
NOTV logo
AnimalDoctorKwon on Inotiv ·

Inotiv NAMs Test Center

Fair Value:US$1.275.7% undervalued
19 users have followed this narrative
2 users have commented on this narrative
5 users have liked this narrative
TH
CGNT logo
TheValueDetector on Cognyte Software ·

This isn’t speculation — this is confirmation.A Schedule 13G was filed, not a 13D, meaning this is passive institutional capital, not acti

Fair Value:US$95.6792.6% undervalued
23 users have followed this narrative
2 users have commented on this narrative
4 users have liked this narrative

Updated Narratives

CA
Canderous
TAL logo
Canderous on PetroTal ·

Beyond 2026, Beyond a Double

Fair Value:CA$1.8178.2% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AG
Agricola
AUMB logo
Agricola on 1911 Gold ·

A case for TSXV:AUMB to reach USD$2.69 (CAD$3.70) by 2030 (15X).

Fair Value:CA$3.774.9% undervalued
19 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
CO
composite32
FRU logo
composite32 on Freehold Royalties ·

Freehold: Offers a fantastic growth-income intersection up to $50 WTI. Below $50 WTI, it may offer historic opportunities in terms of ROI.

Fair Value:CA$19.3811.9% undervalued
6 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

DA
davidlsander
UBI logo
davidlsander on Ubisoft Entertainment ·

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share

Fair Value:€33.887.4% undervalued
59 users have followed this narrative
5 users have commented on this narrative
25 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$59633.4% undervalued
1279 users have followed this narrative
2 users have commented on this narrative
9 users have liked this narrative
TA
Talos
TSLA logo
Talos on Tesla ·

The "Physical AI" Monopoly – A New Industrial Revolution

Fair Value:US$665.3638.3% undervalued
45 users have followed this narrative
19 users have commented on this narrative
22 users have liked this narrative

Trending Discussion

Advertisement